Aged garlic extract 2,400 mg/day,
does it really help with Reduced progression of low-attenuation coronary plaque in metabolic syndrome?
research showsGrade C with 46 points. In a trial with 65 registered and 55 analyzed, percent LAP change was -1.5% versus +0.2% (P=.0049), with adjusted beta -1.61 (95% CI -2.79 to -0.43; P=.008). It was a company-supported small imaging study, and a prespecified LAP-only primary hierarchy and full ITT analysis are unverified.
ads claimThis cannot be described as eliminating plaque or preventing myocardial infarction.
Useful facts when choosing a product
- This verdict applies only to the displayed formulation, route, dose, duration, population, endpoint, and comparator.
- Raw garlic, powder, garlic oil, stabilized-allicin products, aged garlic extract, black garlic, fermented garlic, and isolated S-allylcysteine are not interchangeable.
- Caution. This imaging trial does not settle long-term bleeding or interaction risks; review anticoagulant, antiplatelet, and perioperative use with a clinician.
Chamgap Semantic Classification Code
Permanent code issued
S.aged-garlic-extract.oral-addon.low-attenuation-coronary-plaque.reduce.placeboSupplements and nutraceuticals > Aged garlic extract > Oral add-on > Low-attenuation coronary plaque > Reduction claim > Placebo plus usual care
Issued only for low-attenuation plaque on CCTA; total plaque, calcification, and clinical events remain separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Aged garlic extract |
| Source or part used | Aged extract of Allium sativum L. cloves |
| Formulation or processing | AGE capsules; exact SAC specification unverified |
| Route | Oral add-on |
| Dose | 2,400 mg/day |
| Duration | About 12 months; CCTA interval 354±41 days |
| Population | 55 adults with metabolic syndrome continuing usual risk-factor care |
| Effect or condition | Reduced low-attenuation plaque progression |
| Primary endpoint | Change in percent low-attenuation plaque volume on CCTA |
| Comparator | Matching placebo plus usual care |
| Duplicate-detection key | Aged garlic extract|AGE capsules; exact SAC specification unverified|Oral add-on|55 adults with metabolic syndrome continuing usual risk-factor care|Reduced low-attenuation plaque progression|About 12 months; CCTA interval 354±41 days |
What the research actually shows
Unadjusted and adjusted estimates from NCT01534910 were separated; trials of AGE combined with B vitamins, folate, and L-arginine were excluded.
Why this is classified as C (46)
This is S/R1/I0 and EX because the prespecified LAP-only hierarchy and clinical threshold are unclear; analysis of 55 of 65 participants and industry support yield C/46.
Counterpoint. A separate diabetes trial also showed an LAP signal but shared the product sponsor and research lineage, so it was not counted as independent R2 replication.
Rejudgment record. Independent Codex cross-check — One formulation, route, population, claim, principal endpoint, and comparator
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Aged Garlic Extract Reduces Low Attenuation Plaque in Coronary Arteries of Patients with Metabolic Syndrome in a Prospective Randomized Double-Blind Study | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 28 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-08).
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Aged Garlic Extract for Low-Attenuation Coronary Plaque—A One-Year CCTA Signal Without Secure Primary-Outcome Confirmation — Evidence Grade C·46. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/aged-garlic-extract-metabolic-syndrome-low-attenuation-coronary-plaque/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.